new glp-1 agonists Are Serious Anesthesia Risks of Semaglutide and Other Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia GLP-1 Agonists Market Report 2025-2033,

*Correspondence: Sui-yi Xu, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

NICE has published guidance on pharmacological interventions for weight management, including NICE guideline CG189 (Obesity: identification, assessment and management) and a technology appraisal supporting the use of semaglutide (Wegovy) for adults with a BMI of 35 kg/m or above (or 3034.9 kg/m in certain circumstances) alongside a specialist weight management service

doi:10.18699/vjgb-25-61

Glutathione treatment of dyspermia: effect on the lipoperoxidation process

10.1039/d4fo01929f 55 FoudaA